practolol has been researched along with Heart Failure in 77 studies
Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.
practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A single-blind study of prenalterol 20-200 mg daily in a slow-release tablet preparation and a placebo was performed in 15 patients with moderate to severe congestive heart failure (NYHA II-IV) to evaluate the haemodynamic and clinical effects of oral prenalterol." | 9.05 | Effects of prenalterol administered orally in patients with congestive heart failure. ( Abelardo, N; Caidahl, K; Estrada-Yamamoto, M; Hjalmarson, A; Reyes, C; Waagstein, F; Wallentin, I; Wikstrand, J, 1982) |
| "Prenalterol, a beta1 agonist, was given in a single blind acute intravenous study to seven patients with cardiac failure (New York Heart Association class II and III)." | 9.05 | Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure. ( Ashley, J; Currie, PJ; Federman, J; Kelly, MJ; Middlebrook, K; Pitt, A; Sainsbury, E, 1984) |
| "The hemodynamic effect of 75 to 225 microgram/kg prenalterol (PNL) intravenously were studied at rest and during exercise in eight patients with chronic congestive heart failure (CHF) after myocardial infraction (three patients), valvular surgery (three patients), and congestive cardiomyopathy (two patients)." | 9.05 | Clinical results with prenalterol in patients with heart failure. ( Ariniego, R; Hjalmarson, A; Reiz, S; Waagstein, F, 1981) |
| "Ten patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics were randomly allocated to oral treatment with prenalterol (100-200 mg daily in addition to their basal treatment) or to intensified treatment with diuretics in a cross-over trial." | 9.05 | Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial. ( Areskog, M; Dahlström, U; Karlsson, E; Wranne, B, 1984) |
| "In a controlled, randomized, double-blind study we investigated the long-term effects of the beta 1-adrenoceptor agonist prenalterol in 16 patients with severe congestive heart failure (NYHA class III or IV)." | 9.05 | Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. ( Erbel, R; Lambertz, H; Meyer, J, 1984) |
| "Systemic and coronary hemodynamic effects of prenalterol, a beta-1 receptor agonist, were determined in patients with chronic congestive heart failure, initially after intravenous administration (10 patients) and then after oral administration (eight patients)." | 7.67 | Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance. ( Chatterjee, K; Curran, D; Hoyle, MJ; Parmley, WW; Rabbino, M; Swedberg, K; Wahr, DW, 1984) |
| "Prenalterol was administered as an intravenous infusion at three incremental rates (60, 120 and 240 nmol/min) to five patients with severe cardiac failure." | 7.67 | Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure. ( Ashley, JJ; Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG; Sainsbury, EJ, 1985) |
| "The acute haemodynamic effects of oral prenalterol were studied in 14 patients with severe heart failure (NYHA class III) due to ischaemic heart disease." | 7.67 | Acute haemodynamic effects of oral prenalterol in severe heart failure. ( Goodfellow, RM; Ormerod, O; Petch, MC; Scott, C; Wisbey, C, 1984) |
| "?The cardiovascular effects of the cardioselective beta, agonist prenalterol have been studied in nine patients with severe chronic congestive cardiac failure and in six patients with left ventricular dysfunction resulting from previous myocardial infarction." | 7.66 | Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure. ( Hutton, I; Martin, W; Murray, RG; Pearson, D; Tweddel, AC, 1982) |
| "To provide improved inotropic agents for enhanced therapy of severe congestive heart failure (CHF), the hemodynamic efficacy of prenalterol (PN), a recently developed cardioselective beta-1 receptor agonist, was evaluated by cardiac catheterization in nine patients with refractory CHF due to chronic coronary disease." | 7.66 | Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease. ( Awan, NA; Evenson, MK; Mason, DT; Needham, KE; Win, A, 1981) |
| "In 12 patients with severe congestive heart failure due to ischaemic heart disease (n = 6) and due to congestive cardiomyopathy (n = 6) the haemodynamic effects of a new beta 1-agonist, prenalterol, were studied." | 7.66 | Haemodynamic effects of prenalterol in patients with severe congestive heart failure--NYHA III-IV. ( Effert, S; Erbel, R; Lambertz, H; Meyer, J; Schweizer, P; Voelker, W, 1982) |
| "The hemodynamic benefits of combined administration of prenalterol (P) with hydralazine (H) were evaluated in ten patients with severe chronic heart failure." | 7.66 | Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure. ( Drexler, H; Just, H; Löllgen, H, 1981) |
| "The hemodynamic, hormonal and electrolyte effects of prenalterol, a synthetic selective beta 1 agonist, were studied in six patients with New York Heart Association functional class II and III heart failure." | 7.66 | Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "The effects of a single intravenous infusion of prenalterol, a beta 1 selective agonist, on haemodynamics (echocardiography) and venous plasma catecholamine concentration were studied in 8 patients with severe congestive heart failure." | 7.66 | Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure. ( Bentivoglio, M; Corea, L; Provvidenza, M; Verdecchia, P, 1983) |
| "The haemodynamic effects of prenalterol, a new beta-1 agonist, were studied in 10 patients with chronic heart failure." | 7.66 | Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure. ( Coxon, R; Sharpe, DN, 1983) |
| "Prenalterol was well tolerated and produced no increase in frequency of angina or ventricular arrhythmias." | 6.66 | Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo. ( Glover, DR; Littler, WA; Muir, AL; Murray, RG; Petch, MC; Wathen, CG, 1985) |
| " The half-life of the elimination phase is close to 2 hours." | 6.65 | Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure. ( Rönn, O, 1982) |
| "Prenalterol is an orally active cardioselective beta agonist, with a long half-life." | 6.65 | A dose response study with oral prenalterol in patients with chronic congestive cardiac failure. ( Besterman, EM; Comerford, MB; Hendry, WG, 1984) |
| "In a controlled, randomized, double-blind study we investigated the long-term effects of the beta 1-adrenoceptor agonist prenalterol in 16 patients with severe congestive heart failure (NYHA class III or IV)." | 5.05 | Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. ( Erbel, R; Lambertz, H; Meyer, J, 1984) |
| "Ten patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics were randomly allocated to oral treatment with prenalterol (100-200 mg daily in addition to their basal treatment) or to intensified treatment with diuretics in a cross-over trial." | 5.05 | Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial. ( Areskog, M; Dahlström, U; Karlsson, E; Wranne, B, 1984) |
| "Prenalterol, a beta1 agonist, was given in a single blind acute intravenous study to seven patients with cardiac failure (New York Heart Association class II and III)." | 5.05 | Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure. ( Ashley, J; Currie, PJ; Federman, J; Kelly, MJ; Middlebrook, K; Pitt, A; Sainsbury, E, 1984) |
| "The hemodynamic effect of 75 to 225 microgram/kg prenalterol (PNL) intravenously were studied at rest and during exercise in eight patients with chronic congestive heart failure (CHF) after myocardial infraction (three patients), valvular surgery (three patients), and congestive cardiomyopathy (two patients)." | 5.05 | Clinical results with prenalterol in patients with heart failure. ( Ariniego, R; Hjalmarson, A; Reiz, S; Waagstein, F, 1981) |
| "A single-blind study of prenalterol 20-200 mg daily in a slow-release tablet preparation and a placebo was performed in 15 patients with moderate to severe congestive heart failure (NYHA II-IV) to evaluate the haemodynamic and clinical effects of oral prenalterol." | 5.05 | Effects of prenalterol administered orally in patients with congestive heart failure. ( Abelardo, N; Caidahl, K; Estrada-Yamamoto, M; Hjalmarson, A; Reyes, C; Waagstein, F; Wallentin, I; Wikstrand, J, 1982) |
| "Systemic and coronary hemodynamic effects of prenalterol, a beta-1 receptor agonist, were determined in patients with chronic congestive heart failure, initially after intravenous administration (10 patients) and then after oral administration (eight patients)." | 3.67 | Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance. ( Chatterjee, K; Curran, D; Hoyle, MJ; Parmley, WW; Rabbino, M; Swedberg, K; Wahr, DW, 1984) |
| "This paper reports a case of severe low output cardiac failure due to congestive (alcoholic) cardiomyopathy which was unresponsive to dopamine infusion, but which improved rapidly on intravenous practolol therapy." | 3.67 | Marked relief of acute exacerbation of congestive cardiomyopathy by intravenous practolol--report of a case. ( Nieminen, MS; Virtanen, KS, 1984) |
| "The acute haemodynamic effects of oral prenalterol were studied in 14 patients with severe heart failure (NYHA class III) due to ischaemic heart disease." | 3.67 | Acute haemodynamic effects of oral prenalterol in severe heart failure. ( Goodfellow, RM; Ormerod, O; Petch, MC; Scott, C; Wisbey, C, 1984) |
| "Prenalterol was administered as an intravenous infusion at three incremental rates (60, 120 and 240 nmol/min) to five patients with severe cardiac failure." | 3.67 | Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure. ( Ashley, JJ; Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG; Sainsbury, EJ, 1985) |
| "The effects of a single intravenous infusion of prenalterol, a beta 1 selective agonist, on haemodynamics (echocardiography) and venous plasma catecholamine concentration were studied in 8 patients with severe congestive heart failure." | 3.66 | Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure. ( Bentivoglio, M; Corea, L; Provvidenza, M; Verdecchia, P, 1983) |
| "The haemodynamic effects of prenalterol, a new beta-1 agonist, were studied in 10 patients with chronic heart failure." | 3.66 | Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure. ( Coxon, R; Sharpe, DN, 1983) |
| "The hemodynamic, hormonal and electrolyte effects of prenalterol, a synthetic selective beta 1 agonist, were studied in six patients with New York Heart Association functional class II and III heart failure." | 3.66 | Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "The hemodynamic benefits of combined administration of prenalterol (P) with hydralazine (H) were evaluated in ten patients with severe chronic heart failure." | 3.66 | Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure. ( Drexler, H; Just, H; Löllgen, H, 1981) |
| "To assess the immediate haemodynamic and myocardial metabolic effects of the beta 1-agonist prenalterol, we studied by cardiac catheterisation the response to 50 and 100 micrograms/kg given intravenously in 16 patients with congestive heart failure secondary to coronary artery disease or non-ischaemic cardiomyopathy." | 3.66 | Effect of intravenous prenalterol on haemodynamics and myocardial lactate extraction in patients with left ventricular failure. ( Bleifeld, W; Kupper, W; Schütt, M, 1982) |
| "The hemodynamic effects of prenalterol, a parenteral cardioselective beta 1-receptor agonist, were evaluated by cardiac catheterization in patients with refractory severe congestive heart failure (CHF)." | 3.66 | The hemodynamic actions of prenalterol in left ventricular failure. ( Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1982) |
| "To provide improved inotropic agents for enhanced therapy of severe congestive heart failure (CHF), the hemodynamic efficacy of prenalterol (PN), a recently developed cardioselective beta-1 receptor agonist, was evaluated by cardiac catheterization in nine patients with refractory CHF due to chronic coronary disease." | 3.66 | Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease. ( Awan, NA; Evenson, MK; Mason, DT; Needham, KE; Win, A, 1981) |
| "In 12 patients with severe congestive heart failure due to ischaemic heart disease (n = 6) and due to congestive cardiomyopathy (n = 6) the haemodynamic effects of a new beta 1-agonist, prenalterol, were studied." | 3.66 | Haemodynamic effects of prenalterol in patients with severe congestive heart failure--NYHA III-IV. ( Effert, S; Erbel, R; Lambertz, H; Meyer, J; Schweizer, P; Voelker, W, 1982) |
| "?The cardiovascular effects of the cardioselective beta, agonist prenalterol have been studied in nine patients with severe chronic congestive cardiac failure and in six patients with left ventricular dysfunction resulting from previous myocardial infarction." | 3.66 | Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure. ( Hutton, I; Martin, W; Murray, RG; Pearson, D; Tweddel, AC, 1982) |
| "50 patients with stenocardias in persisting arterial hypertension, of them 33 manifest coronary diseases, were orally treated with doses of propranolol up to 400 mg/die during a longer period." | 3.65 | [Therapy of chronic ischemic heart disease and arterial hypertension by means of beta-receptor blockaders]. ( Dück, K; Knappe, J; Strube, G, 1976) |
| "In many patients with chronic atrial fibrillation, it is difficult to prevent an excessive ventricular rate under stress, even with high levels of digoxin in the blood." | 3.65 | Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. ( Kaplinsky, E; Klein, HO; Yahalom, J, 1977) |
| "Prenalterol was well tolerated and produced no increase in frequency of angina or ventricular arrhythmias." | 2.66 | Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo. ( Glover, DR; Littler, WA; Muir, AL; Murray, RG; Petch, MC; Wathen, CG, 1985) |
| "Prenalterol is an orally active cardioselective beta agonist, with a long half-life." | 2.65 | A dose response study with oral prenalterol in patients with chronic congestive cardiac failure. ( Besterman, EM; Comerford, MB; Hendry, WG, 1984) |
| " The half-life of the elimination phase is close to 2 hours." | 2.65 | Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure. ( Rönn, O, 1982) |
| "The possible adverse effects of treatment during pregnancy are also considered." | 2.36 | Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions. ( Beeley, L; Kendall, MJ, 1983) |
| " Adverse and potentially specific reactions to individual beta-blocking agents." | 2.36 | Side effects and contraindications of beta-receptor blocking agents. ( Lydtin, H, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (98.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Y | 1 |
| Guo, C | 1 |
| Zhao, J | 1 |
| Yang, J | 1 |
| Yi, W | 1 |
| Liu, H | 1 |
| Lin, X | 1 |
| Zhang, Z | 1 |
| Sharpe, DN | 2 |
| Reiz, S | 3 |
| Waagstein, F | 6 |
| Hjalmarson, A | 7 |
| Kenakin, TP | 1 |
| Beek, D | 1 |
| Hutton, I | 3 |
| Tweddel, AC | 3 |
| Bastian, BC | 1 |
| Murray, RG | 3 |
| Pearson, D | 1 |
| Martin, W | 1 |
| Lambertz, H | 3 |
| Erbel, R | 3 |
| Meyer, J | 3 |
| Schweizer, P | 2 |
| Effert, S | 2 |
| Voelker, W | 1 |
| Abelardo, N | 2 |
| Caidahl, K | 1 |
| Reyes, C | 2 |
| Wallentin, I | 3 |
| Wikstrand, J | 1 |
| Estrada-Yamamoto, M | 2 |
| Guazzi, MD | 1 |
| Qing, LG | 1 |
| Olivari, MT | 1 |
| Fiorentini, C | 1 |
| Loaldi, A | 1 |
| Bartorelli, A | 2 |
| Moruzzi, P | 2 |
| Polese, A | 1 |
| Awan, NA | 2 |
| Evenson, MK | 2 |
| Needham, KE | 2 |
| Mason, DT | 2 |
| Kupper, W | 2 |
| Schütt, M | 2 |
| Bleifeld, W | 2 |
| Doering, W | 1 |
| Wauer, B | 1 |
| Isbary, J | 1 |
| Drexler, H | 2 |
| Löllgen, H | 2 |
| Just, H | 2 |
| Leinberger, H | 1 |
| Mäurer, W | 2 |
| Haueisen, H | 1 |
| Schuler, G | 1 |
| Kübler, W | 2 |
| Rönn, O | 1 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| Dahlström, U | 4 |
| Karlsson, E | 4 |
| Klein, G | 1 |
| Wirtzfeld, A | 1 |
| Schnelle, K | 1 |
| Javernaro, A | 1 |
| Bolognesi, R | 1 |
| Giacometti, P | 1 |
| Potenza, D | 1 |
| Cortesi, G | 1 |
| Cucchini, F | 1 |
| Kendall, MJ | 1 |
| Beeley, L | 1 |
| Hamm, CW | 1 |
| Kuck, KH | 1 |
| Hanrath, P | 1 |
| Shevchenko, VA | 1 |
| Corea, L | 1 |
| Bentivoglio, M | 1 |
| Verdecchia, P | 1 |
| Provvidenza, M | 1 |
| Roubin, GS | 1 |
| Choong, CY | 1 |
| Devenish-Meares, S | 1 |
| Sadick, NN | 1 |
| Fletcher, PJ | 1 |
| Kelly, DT | 1 |
| Harris, PJ | 1 |
| Nelson, GI | 1 |
| Silke, B | 1 |
| Ahuja, RC | 1 |
| Walker, C | 1 |
| Forsyth, DR | 1 |
| Verma, SP | 1 |
| Taylor, SH | 1 |
| Petch, MC | 2 |
| Wisbey, C | 1 |
| Ormerod, O | 1 |
| Scott, C | 1 |
| Goodfellow, RM | 1 |
| Areskog, M | 1 |
| Wranne, B | 2 |
| Smith, JW | 1 |
| Pouleur, H | 1 |
| Detry, JM | 1 |
| Mancia, G | 1 |
| Brandt, D | 1 |
| Klein, W | 1 |
| Currie, PJ | 1 |
| Kelly, MJ | 1 |
| Middlebrook, K | 1 |
| Federman, J | 2 |
| Sainsbury, E | 1 |
| Ashley, J | 1 |
| Pitt, A | 2 |
| Larbig, D | 1 |
| Nasse, H | 1 |
| Coxon, R | 1 |
| Hendry, WG | 1 |
| Comerford, MB | 1 |
| Besterman, EM | 1 |
| Wahr, DW | 1 |
| Swedberg, K | 1 |
| Rabbino, M | 1 |
| Hoyle, MJ | 1 |
| Curran, D | 1 |
| Parmley, WW | 1 |
| Chatterjee, K | 1 |
| Virtanen, KS | 1 |
| Nieminen, MS | 1 |
| Fitzpatrick, D | 2 |
| Ikram, H | 2 |
| Nicholls, MG | 2 |
| Espiner, EA | 2 |
| Rae, AP | 1 |
| Graffner, C | 1 |
| Jonsson, U | 1 |
| Hoffmann, KJ | 1 |
| Lagerström, PO | 1 |
| Cipolla, CM | 1 |
| Reggiani, P | 1 |
| Guazzi, M | 1 |
| Turton, CW | 1 |
| Waagstein, E | 1 |
| Ariniego, R | 1 |
| Win, A | 1 |
| Kirlin, PC | 1 |
| Pitt, B | 1 |
| Lydtin, H | 1 |
| Frishman, W | 1 |
| Silverman, R | 1 |
| Strom, J | 1 |
| Elkayam, U | 1 |
| Sonnenblick, E | 1 |
| Cairns, JA | 1 |
| Whitford, JA | 1 |
| Anderson, ST | 1 |
| Zacharoulis, AA | 1 |
| Evans, TR | 1 |
| Ziady, GM | 1 |
| Coltart, DJ | 1 |
| Shillingford, JP | 1 |
| Yahalom, J | 1 |
| Klein, HO | 1 |
| Kaplinsky, E | 1 |
| Dück, K | 1 |
| Strube, G | 1 |
| Knappe, J | 1 |
| Varnauskas, E | 2 |
| Glover, DR | 1 |
| Wathen, CG | 2 |
| Muir, AL | 2 |
| Littler, WA | 1 |
| Vahanian, A | 1 |
| Le Potier, J | 1 |
| Sergent, J | 1 |
| Michel, PL | 1 |
| Acar, J | 1 |
| Sainsbury, EJ | 2 |
| Ashley, JJ | 2 |
| Andersson, KE | 1 |
| Korewicki, J | 1 |
| Opolski, G | 1 |
| Ostrzycki, A | 1 |
| Zieliński, T | 1 |
| Jankowski, K | 1 |
| Schwarz, KR | 1 |
| Hofmann, M | 1 |
| Kadel, C | 1 |
| von Olshausen, K | 1 |
| Rauch, B | 1 |
| Brisse, B | 1 |
| Bräuer, B | 1 |
| Müller, W | 1 |
| Gradaus, D | 1 |
| Bender, F | 1 |
| Singh, BN | 1 |
| Simpson, FO | 1 |
| Shah, PM | 1 |
| Adelman, AG | 2 |
| Wigle, ED | 2 |
| Gobel, FL | 1 |
| Burchell, HB | 1 |
| Hardarson, T | 1 |
| Curiel, R | 1 |
| De La Calzada, C | 1 |
| Oakley, CM | 2 |
| Goodwin, JF | 3 |
| Vormittag, E | 1 |
| Goodwin, JE | 1 |
| Felderhof, CH | 1 |
11 reviews available for practolol and Heart Failure
| Article | Year |
|---|---|
Newer inotropic agents.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Dobutamine; Ethanolamines; Heart Failure; Humans; Prac | 1984 |
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions.
Topics: Adrenergic beta-Antagonists; Bradycardia; Brain; Drug Eruptions; Drug Interactions; Eye Diseases; Fe | 1983 |
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators].
Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Hea | 1983 |
[Catecholamines in the therapy of chronic cardiac insufficiency].
Topics: Cardiotonic Agents; Catecholamines; Dobutamine; Dopamine; Epinephrine; Heart Failure; Humans; Isopro | 1982 |
Pleural effusions.
Topics: Alkylating Agents; Asbestosis; Biopsy, Needle; Female; Heart Failure; Hodgkin Disease; Humans; Lymph | 1980 |
Side effects and contraindications of beta-receptor blocking agents.
Topics: Adrenergic beta-Antagonists; Adult; Airway Resistance; Arrhythmias, Cardiac; Blood Vessels; Central | 1977 |
Myocardial infarction size: measurement and modification.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Coronary Disease; Creatine Kinase; Digitalis Glycoside | 1977 |
Some new positive inotropic agents.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; D | 1986 |
Beta-adrenergic receptor blocking drugs in hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alprenolol; Antidepressive Agents; Antihy | 1974 |
The cardiomyopathies.
Topics: Adrenergic beta-Antagonists; Adult; Amyloidosis; Angiography; Cardiac Output; Cardiomyopathies; Cate | 1974 |
16 trials available for practolol and Heart Failure
| Article | Year |
|---|---|
Comparison of the vasodilator prazosin and the selective beta1 agonist prenalterol on rest and exercise haemodynamics in CHF.
Topics: Adrenergic beta-Agonists; Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Hemodynamics; H | 1981 |
[Long-term effect of a new beta-agonist prenalterol in patients with severe congestive heart failure (author's transl)].
Topics: Adrenergic beta-Agonists; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Female; H | 1982 |
Effects of prenalterol administered orally in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Cardiac Output; Delayed | 1982 |
Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Cardiac Catheterization; Cardiac Output; Dose-Respon | 1982 |
Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Biological Availability; Delayed-Action Prepa | 1982 |
Prenalterol in the treatment of congestive heart failure developing during beta-blocking therapy. A comparison with frusemide in patients with acute myocardial infarction.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Blood Pressure; Dose-Response Relationship, D | 1982 |
Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure.
Topics: Adrenergic beta-Agonists; Adult; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Fe | 1984 |
Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Double-Blind Method; Drug Evaluation; Exercis | 1984 |
Hemodynamic trial of sequential treatment with diuretic, vasodilator, and positive inotropic drugs in left ventricular failure following acute myocardial infarction.
Topics: Adrenergic beta-Agonists; Adult; Cardiotonic Agents; Drug Therapy, Combination; Furosemide; Heart Fa | 1984 |
Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial.
Topics: Adrenergic beta-Agonists; Aged; Carcinogens; Chronic Disease; Clinical Trials as Topic; Electrocardi | 1984 |
Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
Topics: Administration, Oral; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Hemodynamics; Hu | 1984 |
A dose response study with oral prenalterol in patients with chronic congestive cardiac failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Exercise Test; | 1984 |
Clinical results with prenalterol in patients with heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemod | 1981 |
Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
Topics: Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Coronary Disease; D | 1985 |
[Chronic therapy of congestive cardiomyopathy: effects of prenalterol and digoxin].
Topics: Adult; Cardiac Output; Cardiac Volume; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials | 1985 |
[New viewpoints on the effect of beta-receptor blockaders].
Topics: Adrenergic beta-Antagonists; Alprenolol; Clinical Trials as Topic; Heart Failure; Humans; Male; Nore | 1973 |
50 other studies available for practolol and Heart Failure
| Article | Year |
|---|---|
X indening oral liquid improves cardiac function of rats with chronic cardiac failure via TGF-ß1/Smad3 and p38 MAPK pathway.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models, Animal; Drugs | 2017 |
Clinical experience of a new inotropic agent--Prenalterol--in hypotension and heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anesthesia, Epidural; Cardiac Output, Low; Cardiotonic Age | 1980 |
In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure.
Topics: Adrenergic beta-Agonists; Animals; Coronary Vessels; Dogs; Female; Guinea Pigs; Heart; Heart Failure | 1982 |
Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Heart; Heart Failure; Hemodynamics; Humans; Male; Midd | 1982 |
Haemodynamic effects of prenalterol in patients with severe congestive heart failure--NYHA III-IV.
Topics: Adrenergic beta-Agonists; Blood Pressure; Cardiac Catheterization; Cardiomyopathies; Coronary Diseas | 1982 |
Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
Topics: Adrenergic beta-Agonists; Aged; Blood Pressure; Coronary Disease; Female; Heart; Heart Failure; Hear | 1982 |
Circulatory response to prenalterol in normal subjects and in patients with primary congestive cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adult; Blood Circulation; Blood Pressure; Cardiac Catheterization; Cardiac | 1982 |
The hemodynamic actions of prenalterol in left ventricular failure.
Topics: Adrenergic beta-Agonists; Aged; Blood Pressure; Cardiac Catheterization; Cardiac Output; Dose-Respon | 1982 |
Effect of intravenous prenalterol on haemodynamics and myocardial lactate extraction in patients with left ventricular failure.
Topics: Adrenergic beta-Agonists; Adult; Blood Pressure; Cardiac Catheterization; Cardiac Output; Coronary C | 1982 |
Effects of i.v. prenalterol in patients with severe cardiac failure at rest and during exercise.
Topics: Adrenergic beta-Agonists; Cardiac Catheterization; Cardiac Output; Cardiomyopathies; Female; Heart; | 1982 |
Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Blood Pressure; Cardiac Catheterization; Cardiac Out | 1982 |
[Therapy of heart failure with beta adrenoceptor agonists].
Topics: Adrenergic beta-Agonists; Dobutamine; Dopamine; Heart Failure; Humans; Practolol; Prenalterol | 1983 |
[Effects of Prenalterol on left ventricular function of coronary patients].
Topics: Adrenergic beta-Agonists; Adult; Heart Failure; Heart Rate; Humans; Middle Aged; Myocardial Contract | 1983 |
Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure.
Topics: Adrenergic beta-Agonists; Adult; Aged; Drug Tolerance; Female; Heart Failure; Hemodynamics; Humans; | 1983 |
Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure.
Topics: Adrenergic beta-Agonists; Aged; Cardiotonic Agents; Catecholamines; Echocardiography; Female; Heart | 1983 |
Acute haemodynamic effects of oral prenalterol in severe heart failure.
Topics: Adrenergic beta-Agonists; Adult; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pra | 1984 |
Mortality after recovery from myocardial infarction.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Heart Failure; Humans; Myocardi | 1980 |
Inotropic drugs of the future.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Imidazoles; Practolol; Prenalte | 1982 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; | 1983 |
Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure.
Topics: Administration, Oral; Aged; Delayed-Action Preparations; Echocardiography; Female; Heart Failure; He | 1983 |
Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
Topics: Administration, Oral; Adult; Aged; Catecholamines; Chronic Disease; Coronary Circulation; Female; He | 1984 |
Marked relief of acute exacerbation of congestive cardiomyopathy by intravenous practolol--report of a case.
Topics: Acute Disease; Adult; Cardiomyopathy, Dilated; Heart Failure; Humans; Injections, Intravenous; Male; | 1984 |
Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
Topics: Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hormones; Humans; Infusions, Parenter | 1983 |
The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
Topics: Catecholamines; Dobutamine; Dopamine; Ethanolamines; Heart Failure; Hemodynamics; Humans; Practolol; | 1983 |
Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.
Topics: Administration, Oral; Aged; Biological Availability; Biotransformation; Delayed-Action Preparations; | 1983 |
[Circulatory effects of prenalterol (selective beta-1 agonist) in normal subjects and in patients with primary congestive cardiomyopathy].
Topics: Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Heart Failure; Heart Rate; Humans; Practolo | 1982 |
Hemodynamic effects of intravenous prenalterol in patients on long-term digoxin therapy for congestive heart failure.
Topics: Aged; Cardiac Output; Cardiotonic Agents; Digoxin; Female; Heart Failure; Heart Rate; Hemodynamics; | 1982 |
Effects of prenalterol in congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; | 1982 |
Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output, Low; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; H | 1981 |
Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.
Topics: Aged; Blood Pressure; Coronary Disease; Electrocardiography; Female; Heart Failure; Heart Rate; Hemo | 1981 |
Hemodynamic effects of intravenous prenalterol in severe heart failure.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Output, Low; Cardiotonic Agents; Female; Heart Failure; Hemodyna | 1981 |
Alternatives to practolol - the argument in more detail.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Oxprenolol; Practolol; Propranolol | 1975 |
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bronchi; Central Nervous System Diseases; Deafnes | 1979 |
Incidence of ventricular arrhythmias in first year after myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Aspartate Aminotransferases; Electrocardiography; Female; Heart F | 1978 |
Measurement of stroke volume from pulmonary artery pressure record in man.
Topics: Blood Pressure; Cardiac Catheterization; Cardiac Output; Cardiomyopathy, Hypertrophic; Catecholamine | 1975 |
Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Drug Evaluation; F | 1977 |
[Therapy of chronic ischemic heart disease and arterial hypertension by means of beta-receptor blockaders].
Topics: Adult; Coronary Disease; Heart Failure; Humans; Hypertension; Middle Aged; Practolol; Propranolol | 1976 |
Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.
Topics: Adult; Alprenolol; Blood Pressure; Cardiac Output; Cardiac Volume; Diuretics; Female; Heart Failure; | 1975 |
Proceedings: Chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.
Topics: Alprenolol; Heart Failure; Humans; Practolol | 1976 |
[Positive inotropic agents. Generalities and classification].
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Calcium; Cardiotonic Agents; Digitalis Glycoside | 1985 |
Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Dose-Response Relationship, Drug; Electrolytes; Heart | 1985 |
The correlation between CK MB curve type and the clinical course of recent myocardial infarction.
Topics: Adult; Aged; Creatine Kinase; Heart Failure; Humans; Isoenzymes; Middle Aged; Myocardial Infarction; | 1988 |
Curve-fitting in pharmacokinetics--a comparison between gamma- and biexponential fits.
Topics: Heart Failure; Humans; Kinetics; Models, Biological; Practolol; Prenalterol | 1986 |
Alternatives to digitalis glycosides for heart failure.
Topics: Digitalis Glycosides; Heart Failure; Humans; Practolol; Prenalterol | 1985 |
Clinical aspects of the anti-arrhythmic actions of beta-receptor blocking drugs. 2. Clinical pharmacology.
Topics: Adrenergic beta-Antagonists; Alprenolol; Arrhythmias, Cardiac; Drug Therapy, Combination; Heart Fail | 1973 |
The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure; Cardiomyopathies; Child; Child, Preschool; Dea | 1974 |
[The influence of beta receptor blockade on the incidence of postoperative cardiovascular complications (author's transl)].
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Myocardial Infarction; Postoperative Complicatio | 1974 |
Relationships among hypertrophy, hypertension, and coronary arterial patterns, and pharmacological responses in cardiomyopathies.
Topics: Cardiomegaly; Cardiomyopathy, Hypertrophic; Coronary Disease; Coronary Vessels; Glucagon; Heart Fail | 1973 |
Treatment of hypertrophic cardiomyopathy (HOCM).
Topics: Cardiomegaly; Heart Failure; Heart Rate; Humans; Physical Exertion; Practolol | 1973 |
Medical and surgical treatment of the cardiomyopathies.
Topics: Alcohol Drinking; Anticoagulants; Cardiomyopathies; Cardiomyopathy, Hypertrophic; Diet, Sodium-Restr | 1974 |